Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (54)
  • Open Access

    ARTICLE

    Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development

    WEITAO ZHENG1, DONG JIANG2, SONGEN CHEN1, MEILING WU1, BAOQI YAN2, JIAHUI ZHAI2, YUNQIANG SHI2, BIN XIE1, XINGWANG XIE2, KANGHONG HU1,*, WENXUE MA3,*

    Oncology Research, Vol.32, No.12, pp. 1837-1850, 2024, DOI:10.32604/or.2024.056565 - 13 November 2024

    Abstract Objectives: The Kirsten rat sarcoma virus (KRAS) G12D oncogenic mutation poses a significant challenge in treating solid tumors due to the lack of specific and effective therapeutic interventions. This study aims to explore innovative approaches in T cell receptor (TCR) engineering and characterization to target the KRAS G12D7-16 mutation, providing potential strategies for overcoming this therapeutic challenge. Methods: In this innovative study, we engineered and characterized two T cell receptors (TCRs), KDA11-01 and KDA11-02 with high affinity for the KRAS G12D7-16 mutation. These TCRs were isolated from tumor-infiltrating lymphocytes (TILs) derived from tumor tissues of patients More >

  • Open Access

    REVIEW

    Impact of nanoparticles on immune cells and their potential applications in cancer immunotherapy

    JYOTHI B. NAIR1,2, ANU MARY JOSEPH3, SANOOP P.4, MANU M. JOSEPH5,*

    BIOCELL, Vol.48, No.11, pp. 1579-1602, 2024, DOI:10.32604/biocell.2024.054879 - 07 November 2024

    Abstract Nanoparticles represent a heterogeneous collection of materials, whether natural or synthetic, with dimensions aligning in the nanoscale. Because of their intense manifestation with the immune system, they can be harvested for numerous bio-medical and biotechnological advancements mainly in cancer treatment. This review article aims to scrutinize various types of nanoparticles that interact differently with immune cells like macrophages, dendritic cells, T lymphocytes, and natural killer (NK) cells. It also underscores the importance of knowing how nanoparticles influence immune cell functions, such as the production of cytokines and the presentation of antigens which are crucial for… More >

  • Open Access

    REVIEW

    Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

    PAULINA CHMIEL1,2, ALEKSANDRA SłOWIKOWSKA1,2, ŁUKASZ BANASZEK1,2, ANNA SZUMERA-CIEćKIEWICZ3, BARTłOMIEJ SZOSTAKOWSKI1, MATEUSZ J. SPAłEK1,4,*, TOMASZ ŚWITAJ1, PIOTR RUTKOWSKI1, ANNA M. CZARNECKA1

    Oncology Research, Vol.32, No.7, pp. 1141-1162, 2024, DOI:10.32604/or.2024.050350 - 20 June 2024

    Abstract Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult… More >

  • Open Access

    ARTICLE

    Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience

    CONSTANTINE N. LOGOTHETIS1, NATHAN P. HORVAT2, TONY KURIAN3, CELESTE BELLO3, JULIO CHAVEZ3, LEIDY ISENALUMHE3, BIJAL SHAH3, LUBOMIR SOKOL3, HAYDER SAEED3, JAVIER PINILLA3, SAMEH GABALLA3,*

    Oncology Research, Vol.32, No.6, pp. 1031-1036, 2024, DOI:10.32604/or.2024.046885 - 23 May 2024

    Abstract Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin’s lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40–81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0–6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was More >

  • Open Access

    ARTICLE

    The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients

    MENNA AL-ADL1,*, MAGDY M. YOUSSEF1, AHMED EL-SEBAIE2, SHERIF REFAAT3, AFAF EL-SAID4

    Oncology Research, Vol.32, No.4, pp. 785-797, 2024, DOI:10.32604/or.2024.047021 - 20 March 2024

    Abstract Cytochromes P450 (CYPs) play a prominent role in catalyzing phase I xenobiotic biotransformation and account for about 75% of the total metabolism of commercially available drugs, including chemotherapeutics. The gene expression and enzyme activity of CYPs are variable between individuals, which subsequently leads to different patterns of susceptibility to carcinogenesis by genotoxic xenobiotics, as well as differences in the efficacy and toxicity of clinically used drugs. This research aimed to examine the presence of the CYP2B6*9 polymorphism and its possible association with the incidence of B-CLL in Egyptian patients, as well as the clinical outcome after… More > Graphic Abstract

    The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients

  • Open Access

    ARTICLE

    SENEX-mediated CDK4/6 inhibition promotes senescence and confers apoptosis resistance in B-cell non-Hodgkin lymphoma

    JIYU WANG1,#, LIUYING YI2,#, KEKE HUANG1, YANGYANG WANG1, HUIPING WANG1, ZHIMIN ZHAI1,*

    BIOCELL, Vol.48, No.3, pp. 453-462, 2024, DOI:10.32604/biocell.2024.047871 - 15 March 2024

    Abstract Background: The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma (r/r B-NHL) is resistance to current therapies, and therapy-induced senescence (TIS) stands out as a crucial mechanism contributing to tumor drug resistance. Here, we analyzed SENEX/Rho GTPase Activating Protein 18 (ARHGAP18) expression and prognostic significance in doxorubicin-induced B-NHL-TIS model and r/r B-NHL patients, investigating its target in B-NHL cell senescence and the effect of combining specific inhibitors on apoptosis resistance in B-NHL-TIS cells. Methods: Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector (Sh-SENEX) and the empty vector… More >

  • Open Access

    ARTICLE

    L’atteinte psychologique des patients marocains suivis pour hémopathie maligne et son impact sur leur qualité de vie

    Maha Ouazzani1,2,*, Zineb El Khammar2, Nawal Oubelkacem2, Youssef Aboussaleh1, Hajar Masrour2, Moncef Maiouak3, Rhizlane Berrady2

    Psycho-Oncologie, Vol.17, No.4, pp. 235-244, 2023, DOI:10.32604/po.2023.044831 - 28 December 2023

    Abstract Introduction : la qualité de vie des patients suivis pour une hémopathie maligne dépend non seulement du type de la maladie, de ses caractéristiques cliniques, biologiques et thérapeutiques, mais aussi de la santé mentale du patient. L’objectif de notre étude est d’évaluer l’état psychologique des patients au diagnostic, de rechercher les facteurs associés à son altération et de préciser son impact sur la qualité de vie des patients. Méthode : nous avons mené une étude monocentrique transversale qui évalue la dépression, l’anxiété et la qualité de vie d’une population de patients atteints de syndromes lymphoprolifératifs sur une… More >

  • Open Access

    ARTICLE

    Effects of platelets on characteristics of lymphocytes cultured in vitro and optimization of adoptive immunotherapy

    CONGLIANG CHEN#, XIAOHONG LENG#, YU ZHANG, JUNMEI HU, DAPENG WEI, PEIPEI WANG*, XIA WANG*

    BIOCELL, Vol.47, No.12, pp. 2661-2669, 2023, DOI:10.32604/biocell.2023.043084 - 27 December 2023

    Abstract Background: T lymphocytes, the main participants of cellular immunity, can express a variety of surface molecules and form different lymphocyte subsets under the induction of different factors to play the functions of immune regulation and immune killing. Studies have shown that platelets play a crucial role in maintaining the stable differentiation of lymphocytes and the balance in immunomodulation. Therefore, it is necessary to study the effect of platelets on lymphocytes in vitro to better understand the role of platelets in the immune system and broaden the application of adoptive immunotherapy. Methods: Cell counting and microscopic observation were… More >

  • Open Access

    ARTICLE

    ScRNA-seq reveals the correlation between M2 phenotype of tumor-associated macrophages and lymph node metastasis of breast cancer

    JUN SHEN1,#, HONGFANG MA2,#, YONGXIA CHEN3, JIANGUO SHEN1,*

    Oncology Research, Vol.31, No.6, pp. 955-966, 2023, DOI:10.32604/or.2023.029638 - 15 September 2023

    Abstract The process of lymphatic metastasis was proved to be associated with podoplanin-expressing macrophages in breast cancer (BC). This study aimed to investigate the role of the M2 phenotype of tumor-associated macrophages and mine the key M2 macrophages-related genes for lymph node metastasis in BC. We downloaded the GSE158399 dataset from the Gene Expression Omnibus (GEO) database, which includes transcriptomic profiles of individual cells from primary tumors, negative lymph nodes (NLNs), and positive lymph nodes (PLNs) of breast cancer patients. The cell subsets were identified by clustering analysis after quality control of the scRNA-seq using Seurat.… More >

  • Open Access

    ARTICLE

    HSP90AA1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition

    FENGXIANG TANG, YANSHI LI, MIN PAN, ZHIHAI WANG, TAO LU, CHUAN LIU, XIN ZHOU, GUOHUA HU*

    Oncology Research, Vol.31, No.5, pp. 787-803, 2023, DOI:10.32604/or.2023.030081 - 21 July 2023

    Abstract Background: Lymphatic metastasis (LM) emerges as an independent prognostic marker for hypopharyngeal squamous cell carcinoma (HSPSCC), chiefly contributing to treatment inefficacy. This study aimed to scrutinize the prognostic relevance of HSP90AA1 and its potential regulatory mechanism of concerning LM in HPSCC. Methods: In a preceding investigation, HSP90AA1, a differential gene, was discovered through transcriptome sequencing of HPSCC tissues, considering both the presence and absence of LM. Validation of HSP90AA1 expression was accomplished via qRT-PCR, western-blotting(WB), and immunohistochemistry(IHC), while its prognostic significance was assessed employing Kaplan–Meier survival analysis(KMSA), log-rank test(LR), and Cox’s regression analysis(CRA). Bioinformatics techniques… More > Graphic Abstract

    HSP90AA1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition

Displaying 1-10 on page 1 of 54. Per Page